Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by 7143309322on Jul 15, 2018 11:06pm
178 Views
Post# 28319343

RE:RE:Big pharma are definitely interested in pli’s Pipeline becau

RE:RE:Big pharma are definitely interested in pli’s Pipeline becau
rapid_fire_ wrote:
edrose wrote: 1- just look at small molecule 4050 and analogues ipf alone if phase 3 successful potential revenue is in the billions and with alstrom data it derisks investment but we still have to prove it in phase 3
   Then nash also worth lot of money again if it works but that’s only in few years but big pharma have money and staff to get this going
2- pg and future proteins also will generate revenue in future and this division low risk it just needs few years and more money

MY CONCERN DO WE HAVE A GOOD EXPERIENCED BUSINESS TEAM TO NEGOTIATE A GREAT DEAL IN BEST INTEREST OF PLI AND IN THEIR OWN INTEREST
ARE THEY WILLING TO ADMIT THAT WE NEED BIG PHARMA TO GROW AND DEV PLI’S POTENTIAL SINCE THEY HAVE MONEY EXPERIENCE TO BRING MEDICATION/PRODUCTS TO MARKET

MY BIGGEST CONCERN WILL PIERRE GIVE UP SOME POWER TO BIG PHARMA WHO MUST HAVE CONCERNS IN HOW OUR CO. AS BEEN MANAGED OVER PAST FEW YEARS;I DONT THINK THEY WILL JUST GIVE MONEY AND PAY FOR PHASE 3 IPF WHICH IS EXPENSIVE WITHOUT HAVING SOME CONTROL OF HOW BUSINESS IS CONDUCTED AND PROTECT THEIR INVESTMENT 


Enrose - I think they ink a deal in rough draft this week . NR to come in a couple weeks with a LOU / LOI .

I think what you think means nothing! 
Bullboard Posts